Posts Tagged ‘liraglutide’

Elusive Billions for Obesity Care

May 2, 2016 — A recent headline in Wired shouted it out: “Diabetes drug that also treats obesity could make billions.” What followed was a mostly reasonable discussion of the risks and benefits of obesity treatment in the jocular tone typical of Wired. Alexa Kurzius explains her assessment of the potential for Saxenda (liraglutide) for obesity: Initially, weight loss was just […]

Calming the Brain’s Response to Food

April 4, 2016 — Your brain’s response to food is one of the key tools that your body uses to protect you from starving or losing too much weight. Even bad food starts looking really good and thoughts about food crowd out everything else in the brain. In a featured presentation at ENDO 2016, Olivia Farr and colleagues demonstrated that […]

Liraglutide CV Outcomes: A Milestone for Diabetes and Obesity

March 7, 2016 — A major new study shows that people treated with liraglutide for type 2 diabetes have fewer strokes, heart attacks, and deaths from heart disease. Six years ago, cardiovascular outcomes had doctors scratching their heads about diabetes and obesity drugs. A hearing on a flawed outcome study with sibutramine resulted in its withdrawal from the market. […]

Big Changes in Drugs for Diabetes and Obesity

January 31, 2016 — Some big changes are in the wind for drugs that treat diabetes and obesity. The biggest selling diabetes drug in the world — Lautus — is facing competition from a lower-priced, biosimilar form of this long-acting form of insulin. Newer drugs like Jardiance (empagliflozin) and Victoza (liraglutide) are growing robustly, valued for their profile for […]

Advancing Obesity Care in Step with Diabetes Care

January 7, 2016 — A new review of advances in obesity care adds reasons to think that these advances are synergistic with advances in diabetes care. John Dixon highlights three major advances in obesity care from 2015 and all of them relate to diabetes as well. Liraglutide. Dixon cites impressive evidence that this drug, newly indicated for obesity treatment, is […]

Being Different in Diabetes and Obesity

December 11, 2015 — Being different can be uncomfortable and, sometimes, rewarding. A new review in the Annals of Internal Medicine finds only small differences between a rising crop of new, once-weekly drugs for diabetes called GLP-1 agonists. The investigators found a lot of similarities between the outcomes with these drugs, along with some differences in side effects, body weight, […]

Liraglutide and Heart Disease

November 10, 2015 — If you thought that the onslaught of new studies was done with the closing of ObesityWeek on Friday, think again. Now we have two important new studies of liraglutide and heart disease that were presented at the Annual Scientific Sessions of the American Heart Association (AHA) on Sunday and Monday. The study that’s hogging all the […]

Diabetes Care That Reduces Weight and Extends Life

September 19, 2015 — A remarkable study was published in the New England Journal of Medicine this week, demonstrating that type 2 diabetes care with an SGLT2 inhibitor (empagliflozin) both reduces weight and extends life. Of course, the most remarkable part of the study is the survival benefit that empaglifozin provides. In a randomized, placebo-controlled trial over just three years, the study […]

Suppressing the Brain’s Response to Food Cues

September 11, 2015 — A heightened response to the food cues that surround us is one of the ways that our brains protect us from starving, losing weight, or staying at a reduced weight. When you’re hungry, images of food capture your brain’s attention, look more appealing, and get in the way of focusing on anything else. So a […]

Halfway There in Developing Obesity Care?

August 9, 2015 — Progress in developing obesity care options is very encouraging, and at the same time frustrating. Friday, Novo Nordisk reported on early results from introducing Saxenda — the fourth new obesity treatment in as many years — into the U.S. Uptake is encouraging, with prescriptions that are growing steadily at a volume comparable to other recent introductions. For […]